2020 Q4 Form 10-K Financial Statement
#000156459021010823 Filed on March 04, 2021
Income Statement
| Concept | 2020 Q4 | 2019 Q4 | 2019 |
|---|---|---|---|
| Revenue | $2.030M | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Cost Of Revenue | $2.030M | ||
| YoY Change | |||
| Gross Profit | $0.00 | ||
| YoY Change | |||
| Gross Profit Margin | 0.0% | ||
| Selling, General & Admin | $4.290M | $3.190M | $13.42M |
| YoY Change | 34.48% | -7.54% | 8.66% |
| % of Gross Profit | |||
| Research & Development | $14.56M | $10.79M | $43.86M |
| YoY Change | 34.94% | 30.95% | 104.25% |
| % of Gross Profit | |||
| Depreciation & Amortization | $0.00 | $0.00 | $146.0K |
| YoY Change | -2.01% | ||
| % of Gross Profit | |||
| Operating Expenses | $18.84M | $13.99M | $57.28M |
| YoY Change | 34.67% | 19.78% | 166.73% |
| Operating Profit | -$18.84M | -$57.28M | |
| YoY Change | |||
| Interest Expense | $30.00K | $380.0K | $2.145M |
| YoY Change | -92.11% | -44.93% | -3.77% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$90.00K | -$10.00K | -$39.00K |
| YoY Change | 800.0% | -106.67% | -102.36% |
| Pretax Income | -$18.91M | -$13.61M | -$55.18M |
| YoY Change | 38.94% | 25.55% | 83.57% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$18.91M | -$13.61M | -$55.18M |
| YoY Change | 38.94% | 25.55% | 83.59% |
| Net Earnings / Revenue | -931.53% | ||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$854.9K | -$1.130M | -$4.598M |
| COMMON SHARES | |||
| Basic Shares Outstanding | |||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q4 | 2019 Q4 | 2019 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $79.36M | $76.90M | $76.90M |
| YoY Change | 3.2% | -35.97% | -35.97% |
| Cash & Equivalents | $30.36M | $15.37M | $15.40M |
| Short-Term Investments | $49.00M | $61.50M | $61.50M |
| Other Short-Term Assets | $6.800M | $4.200M | $4.200M |
| YoY Change | 61.9% | 7.69% | 7.69% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $3.313M | $15.00M | $15.00M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $89.51M | $96.07M | $96.10M |
| YoY Change | -6.82% | -22.52% | -22.5% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $433.0K | $304.0K | $2.200M |
| YoY Change | 42.43% | -21.24% | 450.0% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $2.500M | ||
| YoY Change | |||
| Other Assets | $528.0K | $257.0K | $300.0K |
| YoY Change | 105.45% | -52.67% | -40.0% |
| Total Long-Term Assets | $5.336M | $2.488M | $2.500M |
| YoY Change | 114.47% | 167.81% | 177.78% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $89.51M | $96.07M | $96.10M |
| Total Long-Term Assets | $5.336M | $2.488M | $2.500M |
| Total Assets | $94.85M | $98.55M | $98.60M |
| YoY Change | -3.76% | -21.11% | -21.06% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $5.931M | $4.279M | $4.300M |
| YoY Change | 38.61% | 242.87% | 258.33% |
| Accrued Expenses | $9.900M | $9.600M | $9.600M |
| YoY Change | 3.13% | 174.29% | 174.29% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $17.80M | $28.90M | $28.90M |
| YoY Change | -38.42% | 501.94% | 502.08% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $1.000M | $1.300M | $1.300M |
| YoY Change | -23.08% | 550.0% | 550.0% |
| Total Long-Term Liabilities | $1.000M | $1.300M | $1.300M |
| YoY Change | -23.08% | 550.0% | 550.0% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $17.80M | $28.90M | $28.90M |
| Total Long-Term Liabilities | $1.000M | $1.300M | $1.300M |
| Total Liabilities | $18.78M | $30.22M | $30.20M |
| YoY Change | -37.86% | 507.4% | 504.0% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$314.8M | -$258.5M | |
| YoY Change | 21.75% | 27.14% | |
| Common Stock | $22.00K | $12.00K | |
| YoY Change | 83.33% | 0.0% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $76.07M | $68.34M | $68.30M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $94.85M | $98.55M | $98.60M |
| YoY Change | -3.76% | -21.11% | -21.06% |
Cashflow Statement
| Concept | 2020 Q4 | 2019 Q4 | 2019 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$18.91M | -$13.61M | -$55.18M |
| YoY Change | 38.94% | 25.55% | 83.59% |
| Depreciation, Depletion And Amortization | $0.00 | $0.00 | $146.0K |
| YoY Change | -2.01% | ||
| Cash From Operating Activities | -$22.10M | -$8.100M | -$43.61M |
| YoY Change | 172.84% | -10.99% | 52.74% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$100.0K | $0.00 | -$100.0K |
| YoY Change | -100.0% | -126.6% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $27.60M | $500.0K | $27.50M |
| YoY Change | 5420.0% | -88.64% | -138.79% |
| Cash From Investing Activities | $27.60M | $400.0K | $27.39M |
| YoY Change | 6800.0% | -90.48% | -138.41% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 0.000 | 0.000 | 327.0K |
| YoY Change | -99.71% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -22.10M | -8.100M | -43.61M |
| Cash From Investing Activities | 27.60M | 400.0K | 27.39M |
| Cash From Financing Activities | 0.000 | 0.000 | 327.0K |
| Net Change In Cash | 5.500M | -7.700M | -15.89M |
| YoY Change | -171.43% | 57.14% | -238.72% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$22.10M | -$8.100M | -$43.61M |
| Capital Expenditures | -$100.0K | $0.00 | -$100.0K |
| Free Cash Flow | -$22.00M | -$8.100M | -$43.51M |
| YoY Change | 171.6% | -8.99% | 50.41% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y8M15D | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y1M24D | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y11M15D | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P7Y1M20D | |
| CY2020 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
20948000 | |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
17796000 | |
| CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
28899000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
981000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1319000 | |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
18777000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
15369000 | |
| CY2019Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
61496000 | |
| CY2019Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
15000000 | |
| CY2019Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4201000 | |
| CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
96066000 | |
| CY2020Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
2543000 | |
| CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
528000 | |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1832000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
433000 | |
| CY2020Q4 | us-gaap |
Assets
Assets
|
94846000 | |
| CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5931000 | |
| CY2020Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
2476000 | |
| CY2020Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
1983000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
663000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
483000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22097820 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22097820 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
12040835 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
12040835 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
49000000.0 | |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
5000 | |
| CY2019Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
34000 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-314761000 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-258520000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
76069000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
68336000 | |
| CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
94846000 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
98554000 | |
| CY2019 | us-gaap |
Operating Expenses
OperatingExpenses
|
57277000 | |
| CY2020 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.93 | |
| CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-55178000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
119945000 | |
| CY2019 | cbio |
Stock Issued During Period From Espp Purchases And Stock Options Exercised Value
StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue
|
327000 | |
| CY2020 | cbio |
Stock Issued During Period From Espp Purchases And Stock Options Exercised Value
StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue
|
435000 | |
| CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
4559000 | |
| CY2020 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
59941000 | |
| CY2020 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-29000 | |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-56241000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
76069000 | |
| CY2020 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-11687000 | |
| CY2019 | cbio |
Payments To Acquire Short Term And Long Investments
PaymentsToAcquireShortTermAndLongInvestments
|
129977000 | |
| CY2020 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
267000 | |
| CY2020 | cbio |
Payments To Acquire Short Term And Long Investments
PaymentsToAcquireShortTermAndLongInvestments
|
97635000 | |
| CY2019 | cbio |
Increase Decrease In Operating Lease Liability And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset
|
75000 | |
| CY2019 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
15000000 | |
| CY2019 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
64000 | |
| CY2020 | cbio |
Proceeds From Issuance Of Common Stock For Public Offering Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts
|
59941000 | |
| CY2020 | cbio |
Proceeds From Issuance Of Common Stock From Espp Purchases And Stock Option Exercises
ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises
|
435000 | |
| CY2019 | cbio |
Proceeds From Issuance Of Common Stock From Espp Purchases And Stock Option Exercises
ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises
|
327000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
60376000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
327000 | |
| CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
14991000 | |
| CY2019 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-15894000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
15369000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
31263000 | |
| CY2019 | cbio |
Non Cash Or Part Non Cash Right Of Use Asset And Operating Lease Liability Recorded Upon Adoption Net
NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet
|
2052000 | |
| CY2020 | cbio |
Non Cash Or Part Non Cash Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities
NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities
|
476000 | |
| CY2020 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p id="NOTES_TO_CONSOLIDATED" style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of Operations</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. and its subsidiary (the “Company” or “Catalyst”) is a <span style="color:#000000;">fully integrated research and clinical development biopharmaceutical company with expertise in protease engineering, discovery, translational research, clinical development, and manufacturing. The Company is focused on advancing its protease product candidates in the fields of hemostasis and complement regulation.</span> <span style="color:#000000;">The Company is located in South San Francisco, California and operates in</span> one segment. </p> | |
| CY2020 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-56200000 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-314800000 | |
| CY2020 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, operating lease right-of-use assets and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p> | |
| CY2020Q4 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
3300000 | |
| CY2020 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
20900000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
34000 | |
| CY2020Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
81897000 | |
| CY2019Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
76865000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
5000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
81897000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
81897000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
76865000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
76865000 | |
| CY2020 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
2500000 | |
| CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
3979000 | |
| CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
2026000 | |
| CY2020Q4 | cbio |
Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
|
2238000 | |
| CY2019Q4 | cbio |
Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
|
4320000 | |
| CY2020Q4 | cbio |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
291000 | |
| CY2019Q4 | cbio |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
435000 | |
| CY2020Q4 | cbio |
Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
|
235000 | |
| CY2019Q4 | cbio |
Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
|
250000 | |
| CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
6743000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
7031000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
500000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P2Y7M6D | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Lease Not Yet Commenced Description
LesseeOperatingLeaseLeaseNotYetCommencedDescription
|
commenced during the fourth quarter of 2020. | |
| CY2020 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
700000 | |
| CY2019 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
600000 | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y3M29D | |
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y3M29D | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.057 | |
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.060 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
739000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
762000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
259000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
116000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1644000 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
2294000 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
159000 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
1350000 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1091250 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
6.26 | |
| CY2020 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
44605 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
5.04 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
116000 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
250641 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
10.32 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
17930 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
51.12 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2355615 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.59 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
1337000 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1113791 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
10.45 | |
| CY2020Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
823000 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
1255302 | |
| CY2020 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
602000 | |
| CY2019 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
562000 | |
| CY2020Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
85 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.2100 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.2100 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.0000 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.0006 | |
| CY2020 | cbio |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.0058 | |
| CY2019 | cbio |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.0043 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
|
0.1226 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
|
0.1120 | |
| CY2020 | cbio |
Effective Income Tax Rate Reconciliation Derecognition
EffectiveIncomeTaxRateReconciliationDerecognition
|
-0.4455 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2355615 | |
| CY2019 | cbio |
Effective Income Tax Rate Reconciliation Derecognition
EffectiveIncomeTaxRateReconciliationDerecognition
|
0.0000 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.1225 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.3120 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
-0.0038 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
-0.0063 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.0000 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.0000 | |
| CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
3000000.0 | |
| CY2019Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1900000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
1095000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
936000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
29505000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
34392000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
7789000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
9945000 | |
| CY2020Q4 | cbio |
Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
|
7000 | |
| CY2019Q4 | cbio |
Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
|
10000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
38396000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
45283000 | |
| CY2020 | us-gaap |
Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
|
-6900000 | |
| CY2019 | us-gaap |
Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
|
17200000 | |
| CY2020 | cbio |
Research And Development Tax Credit Carry Forwards Derecognized
ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized
|
15200000 | |
| CY2018Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1573000 | |
| CY2019 | cbio |
Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
|
45000 | |
| CY2019 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
253000 | |
| CY2019Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1871000 | |
| CY2020 | cbio |
Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
|
-295000 | |
| CY2020 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
1379000 | |
| CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
2955000 | |
| CY2020Q4 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
| CY2019Q4 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
| CY2020Q4 | us-gaap |
Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
|
0 | |
| CY2019Q4 | us-gaap |
Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
|
0 | |
| CY2020Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
392.70 | |
| CY2020 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
561000 | |
| CY2019 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
2145000 | |
| CY2020 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
659000 | |
| CY2019 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-39000 | |
| CY2020 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
91000 | |
| CY2019 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
7000 | |
| CY2020 | cbio |
Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
|
1129000 | |
| CY2019 | cbio |
Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
|
2099000 | |
| CY2020Q1 | cbio |
Underwriting Commissions And Offering Expenses Payable
UnderwritingCommissionsAndOfferingExpensesPayable
|
2500000 | |
| CY2020Q1 | cbio |
Net Proceeds From Sale Of Common Stock After Deducting Underwriting Commissions And Offering Expenses Payable
NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable
|
32000000.0 | |
| CY2020Q2 | cbio |
Underwriting Commissions And Offering Expenses Payable
UnderwritingCommissionsAndOfferingExpensesPayable
|
2000000.0 | |
| CY2020Q2 | cbio |
Net Proceeds From Sale Of Common Stock After Deducting Underwriting Commissions And Offering Expenses Payable
NetProceedsFromSaleOfCommonStockAfterDeductingUnderwritingCommissionsAndOfferingExpensesPayable
|
28000000.0 | |
| CY2018Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
10194 | |
| CY2018Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
155.73 | |
| CY2019 | cbio |
Class Of Warrant Or Right Forfeited During Period
ClassOfWarrantOrRightForfeitedDuringPeriod
|
2337 | |
| CY2019 | cbio |
Class Of Warrant Or Right Weighted Average Exercise Price Per Warrants Or Right Forfeited
ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited
|
499.50 | |
| CY2019Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
7857 | |
| CY2020 | cbio |
Class Of Warrant Or Right Forfeited During Period
ClassOfWarrantOrRightForfeitedDuringPeriod
|
7772 | |
| CY2020 | cbio |
Class Of Warrant Or Right Weighted Average Exercise Price Per Warrants Or Right Forfeited
ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited
|
49.91 | |
| CY2020 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-56241000 | |
| CY2019 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-55178000 | |
| CY2020 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
19179299 | |
| CY2019 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
12004489 | |
| CY2020 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.93 | |
| CY2019 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-4.60 | |
| CY2020 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2355700 |
